OXFORD, UK--In the first collaboration with its recently formed associate company Cambridge Combinatorial Ltd., Oxford Molecular Group has reached an agreement to jointly provide technical services and consulting in drug design and combinatorial chemistry to Dainippon Pharmaceuticals Co. of Japan for a period of at least a year. The two companies will also help Dainippon establish its own combinatorial chemistry group.
Under terms of the arrangement, Dainippon will pay an initial sum, ongoing research fees, and milestone payments. Oxford Molecular will also receive royalties from any compounds that are ultimately commercialized. Dainippon will retain exclusive rights to the newly designed and synthesized compounds.